ReviewMedical oncology (Northwood, London, England)2025
Tumor-associated neutrophils and neutrophil extracellular traps in lung cancer: antitumor/protumor insights and therapeutic implications.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- From Bone Marrow Reserve to Metastatic Niche: How Neutrophil-Lineage Cells Shape Skeletal Colonization.International journal of molecular sciences · 2026Review
- Spatiotemporal heterogeneity of neutrophil extracellular traps in hepatocellular carcinoma microenvironment and targeted therapy progress.Journal of translational medicine · 2026Review
- Carvacrol-Based Formulations Modulate Sirtuins and Exert Cytotoxic and Antimicrobial Effects in Lung Cancer Models.Antioxidants (Basel, Switzerland) · 2026Article
- Understanding the dual role of granulocyte-macrophage colony-stimulating factor in the lung cancer tumor microenvironment and its therapeutic implications.Translational lung cancer research · 2026Review
- Article
- Mendelian randomization analysis unveils causal associations between immune cells, metabolites, and lung cancer risk.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), remain the leading cause of cancer-related mortality worldwide, with the tumor microenvironment (TME) playing a crucial role in disease progression. Among the immune components of the TME, tumor-associated neutrophils (TANs) and neutrophil extracellular traps (NETs) have garnered increasing attention due to their complex and sometimes contrasting roles in tumor biology. TANs exhibit both protumor and antitumor functions, either promoting lung cancer progression through enhanced tumor cell proliferation, invasion, angiogenesis, and metastasis or exerting antitumor effects by stimulating immune responses and cytotoxicity. Their impact is largely context-dependent and influenced by interactions with other immune cells, particularly T cells, within the lung cancer TME. Additionally, NETs, secreted by neutrophils, play a pivotal role in tumor progression by facilitating tumor growth, invasion, metastasis, and cancer-associated thrombosis. Although the precise mechanisms underlying NET-mediated tumor promotion are not yet fully elucidated, accumulating evidence suggests their significant contribution to lung cancer pathophysiology. This review synthesizes recent findings on the dual roles of TANs, their interactions with T cells, and the emerging molecular insights into NETs in lung cancer. By elucidating the intricate interplay between TANs, NETs, and immune cells, we aim to provide a foundation for the development of novel therapeutic strategies targeting neutrophil-mediated tumor dynamics.
Indexed as
Identifiers
40522596What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.